PRECLINICAL RESEARCH: HEART FAILURE
Reversal of Cardiac Dysfunction After Long-Term Expression of SERCA2a by Gene Transfer in a Pre-Clinical Model of Heart Failure
Yoshiaki Kawase, MD*,
Hung Q. Ly, MD, MSc*, ,
Fabrice Prunier, MD, PhD ,
Djamel Lebeche, PhD*,
Yanfen Shi, MD,
Hongwei Jin, PhD*,
Lahouaria Hadri, PhD*,
Ryuichi Yoneyama, MD, PhD ,
Kozo Hoshino, MD||,
Yoshiaki Takewa, MD, PhD*,
Susumu Sakata, PhD¶,
Richard Peluso, PhD#,
Krisztina Zsebo, PhD**,
Judith K. Gwathmey, VMD, PhD,
Jean-Claude Tardif, MD,
Jean-François Tanguay, MD and
Roger J. Hajjar, MD*,*
* Mount Sinai School of Medicine, New York, New York
Montreal Heart Institute, University of Montreal School of Medicine, Montreal, Quebec, Canada
Université d’Angers, Angers, France
Department of Radiology, University of Tokyo School of Medicine, Tokyo, Japan
|| Department of Cardiovascular Medicine, Kyoto University, Kyoto, Japan
¶ Department of Physiology II, Nara Medical University, Nara, Japan
# Targeted Genetics, Seattle, Washington
** Celladon, Inc., La Jolla, California
Boston Medical Center, Boston, Massachusetts.
Manuscript received October 12, 2007;
revised manuscript received December 5, 2007,
accepted December 10, 2007.
* Reprint requests and correspondence: Dr. Roger J. Hajjar, Mount Sinai School of Medicine, Cardiovascular Research Center, One Gustave Levy Place, Box 1030, New York, New York 10029. (Email: roger.hajjar{at}mssm.edu).
Objectives: The aim of this study was to examine the effects of sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) gene transfer in a swine heart failure (HF) model.
Background: Reduced expression and activity of SERCA2a have been documented in HF. Prior studies have reported the beneficial effects of short-term SERCA2a overexpression in rodent models. However, the effects of long-term expression of SERCA2a in pre-clinical large animal models are not known.
Methods: Yorkshire-Landrace pigs were used (n = 16) to create volume overload by percutaneously severing chordae tendinae of the mitral apparatus with a bioptome to induce mitral regurgitation. At 2 months, pigs underwent intracoronary delivery of either recombinant adeno-associated virus type 1 (rAAV1) carrying SERCA2a under a cytomegalovirus promoter (rAAV1.SERCA2a) (n = 10; group 1) or saline (n = 6; group 2).
Results: At 2 months, study animals were found to be in a compensated state of volume-overload HF (increased left ventricular internal diastolic and systolic diameters [LVIDd and LVIDs]). At 4 months, gene transfer resulted in: 1) positive left ventricular (LV) inotropic effects (adjusted peak left ventricular pressure rate of rise (dP/dt)max/P, 21.2 ± 3.2 s–1 group 1 vs. 15.5 ± 3.0 s–1 group 2; p < 0.01); 2) improvement in LV remodeling (% change in LVIDs –3.0 ± 10% vs. +15 ± 11%, respectively; p < 0.01). At follow-up, brain natriuretic peptide levels remained stable in group 1 after gene transfer, in contrast to rising levels in group 2. Further, cardiac SERCA2a expression was significantly decreased in group 2 whereas in group 1 it was restored to normal levels. There was no histopathological evidence of acute myocardial inflammation or necrosis.
Conclusions: Using a large-animal, volume-overload model of HF, we report that long-term overexpression of SERCA2a by in vivo rAAV1-mediated intracoronary gene transfer preserved systolic function, potentially prevented diastolic dysfunction, and improved ventricular remodeling.
|
Abbreviations and Acronyms
| | BNP = brain natriuretic peptide | | CK = creatine kinase | | dP/dt = peak left ventricular pressure rate | | HF = heart failure | | LV = left ventricle/ventricular | | LVEF = left ventricular ejection fraction | | LVIDd = left ventricular internal diastolic diameter | | LVIDs = left ventricular internal systolic diameter | | MR = mitral valve regurgitation | | rAAV1 = recombinant adeno-associated virus type 1 | | RT-PCR = reverse transcription polymerase chain reaction | | SERCA2a = sarcoplasmic reticulum Ca2+ ATPase | | Tau = time constant of isovolumic relaxation |
|
This article has been cited by other articles:
|
|
|
|
 
P. W. J. Raake, P. Schlegel, J. Ksienzyk, J. Reinkober, J. Barthelmes, S. Schinkel, S. Pleger, W. Mier, U. Haberkorn, W. J. Koch, et al.
AAV6.{beta}ARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model
Eur. Heart J.,
January 19, 2012;
(2012)
ehr447v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Belmonte, K. B. Margulies, and B. C. Blaxall
S100A1: Another Step Toward Therapeutic Development for Heart Failure
J. Am. Coll. Cardiol.,
August 23, 2011;
58(9):
974 - 976.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jessup, B. Greenberg, D. Mancini, T. Cappola, D. F. Pauly, B. Jaski, A. Yaroshinsky, K. M. Zsebo, H. Dittrich, R. J. Hajjar, et al.
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure
Circulation,
July 19, 2011;
124(3):
304 - 313.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Lyon, M. L. Bannister, T. Collins, E. Pearce, A. H. Sepehripour, S. S. Dubb, E. Garcia, P. O'Gara, L. Liang, E. Kohlbrenner, et al.
SERCA2a Gene Transfer Decreases Sarcoplasmic Reticulum Calcium Leak and Reduces Ventricular Arrhythmias in a Model of Chronic Heart Failure
Circ Arrhythm Electrophysiol,
June 1, 2011;
4(3):
362 - 372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kawase, D. Ladage, and R. J. Hajjar
Rescuing the Failing Heart by Targeted Gene Transfer
J. Am. Coll. Cardiol.,
March 8, 2011;
57(10):
1169 - 1180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Mariani, A. Smolic, A. Preovolos, M. J. Byrne, J. M. Power, and D. M. Kaye
Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure
Eur J Heart Fail,
March 1, 2011;
13(3):
247 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Beeri, M. Chaput, J. L. Guerrero, Y. Kawase, C. Yosefy, S. Abedat, I. Karakikes, C. Morel, A. Tisosky, S. Sullivan, et al.
Gene Delivery of Sarcoplasmic Reticulum Calcium ATPase Inhibits Ventricular Remodeling in Ischemic Mitral Regurgitation
Circ Heart Fail,
September 1, 2010;
3(5):
627 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Kontaraki, F. I. Parthenakis, E. G. Nyktari, A. P. Patrianakos, and P. E. Vardas
Myocardial gene expression alterations in peripheral blood mononuclear cells of patients with idiopathic dilated cardiomyopathy
Eur J Heart Fail,
June 1, 2010;
12(6):
541 - 548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Zhang, T. Guo, S. Mishra, N. D. Dalton, E. G. Kranias, K. L. Peterson, D. M. Bers, and J. H. Brown
Phospholamban Ablation Rescues Sarcoplasmic Reticulum Ca2+ Handling but Exacerbates Cardiac Dysfunction in CaMKII{delta}C Transgenic Mice
Circ. Res.,
February 5, 2010;
106(2):
354 - 362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. G. Di Salvo, M. A. Acker, G. W. Dec, and J. G. Byrne
Mitral Valve Surgery in Advanced Heart Failure
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
271 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Dixon and F. G. Spinale
Large Animal Models of Heart Failure: A Critical Link in the Translation of Basic Science to Clinical Practice
Circ Heart Fail,
May 1, 2009;
2(3):
262 - 271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Antoons and K. R. Sipido
Targeting calcium handling in arrhythmias
Europace,
December 1, 2008;
10(12):
1364 - 1369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. O'Donnell, A. Fields, X. Xu, S. A. K. Chowdhury, D. L. Geenen, and J. Bi
Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo
Am J Physiol Heart Circ Physiol,
December 1, 2008;
295(6):
H2483 - H2494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Vinge, P. W. Raake, and W. J. Koch
Gene Therapy in Heart Failure
Circ. Res.,
June 20, 2008;
102(12):
1458 - 1470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
